Comparative in vitro activity of ceftobiprole against Gram-positive cocci.
The activity of ceftobiprole and comparator agents was evaluated against a collection of 880 isolates, comprising 200 meticillin-susceptible Staphylococcus aureus, 200 meticillin-resistant S. aureus, 180 coagulase-negative staphylococci blood isolates, 100 Streptococcuspneumoniae and 200 macrolide-resistant beta-haemolytic streptococci (100 Streptococcus pyogenes and 100 Streptococcus agalactiae). Ceftobiprole showed excellent activity against staphylococci (minimum inhibitory concentrations <or=4 microg/mL), irrespective of their susceptibility to other agents such as oxacillin, linezolid or glycopeptides. Ceftobiprole was also highly active against penicillin-resistant S. pneumoniae and macrolide-resistant beta-haemolytic streptococci, inhibiting 99.6% of all streptococci tested at <or=0.5 microg/mL. Based on these results, ceftobiprole appears to be a promising agent for the treatment of infections caused by multidrug-resistant Gram-positive pathogens.
Betriu
Carmen
C
Servicio de Microbiología Clínica, Hospital Clínico San Carlos, 28040 Madrid, Spain. cbetriu.hcsc@salud.madrid.org
Culebras
Esther
E
Gómez
María
M
López-Fabal
Fátima
F
Rodríguez-Avial
Iciar
I
Picazo
Juan J
JJ
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D003030:Coagulase / Q000235:genetics; D006460:Hemolysin Proteins / Q000378:metabolism; D006801:Humans; D018942:Macrolides / Q000494:pharmacology; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D013211:Staphylococcus aureus / Q000187:drug effects*; D013292:Streptococcus agalactiae / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013297:Streptococcus pyogenes / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D003030:Coagulase; D006460:Hemolysin Proteins; D018942:Macrolides; C443755:ceftobiprole